Experimental immune drug tested in HPV cancers – but trial halted early
NCT ID NCT04630353
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This very early trial tested a single dose of HB-201 in 10 people with HPV 16+ throat or cervical cancer. The goal was to see how the drug affects the immune system, not to treat the cancer. The study was terminated early, so results are limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HB-201
- What this could lead to
- If successful, this could help researchers understand how to boost the immune system against HPV-related cancers.
- What could go wrong
- This was a very early, small trial that was terminated, so results are limited. It is not a treatment study and may not lead to any new therapy.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV 16+ CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States